Director Meghan V. Joyce sold 10,000 shares ($1.3M) on 2026-06-03 via 10b5-1 plan; retains 11.2K shares + 7,908 option shares.
Meghan V. Joyce, a Director at Guardant Health, Inc., executed four separate sales totaling 10,000 shares for $1,269,808.65 at a blended average price of $126.98 on 2026-06-03. This transaction is part of a pre-arranged 10b5-1 trading plan, meaning the sale was scheduled rather than discretionary. Post-transaction, Joyce retains 11.2K non-derivative shares and 7,908 option shares, preserving a substantial equity stake. The stock currently trades at $133.06, representing a 30-day gain of +48.6% and a 90-day gain of +45.9%, and the company is unprofitable (net income of $-112.1M in its most recent full fiscal year), though it recorded annual revenue growth of +32.9%. The scheduled nature of the sale and the magnitude of the divestiture warrant attention to the underlying fundamentals of a high-growth but currently loss-making biotech firm.